24/7 Market News Snapshot 29 April, 2025 – LifeMD, Inc. Common Stock (NASDAQ:LFMD)

April 29, 2025

DENVER, Colo., 29 April, 2025 (www.247marketnews.com) – (NASDAQ:LFMD) are discussed in this article.
LifeMD, Inc. is currently witnessing a significant surge in market activity, trading at approximately $7.327 during pre-market hours, marking an impressive increase of 20.11% from the previous closing price of $6.100. This gain reflects heightened investor interest, supported by a robust trading volume of 1.90 million shares, which signals confidence in the company’s growth trajectory.

Complementing this bullish market performance, LifeMD is at the forefront of virtual healthcare innovation, particularly in obesity management. The company has formed a strategic partnership with NovoCare® Pharmacy to streamline access to Wegovy® (semaglutide), a groundbreaking FDA-approved treatment for obesity. This collaboration facilitates cash-pay patients’ ability to access Wegovy® doses through LifeMD’s advanced virtual care platform, dramatically simplifying the process of obtaining vital medications.

The comprehensive weight management program offered by LifeMD integrates virtual consultations with lab testing, lifestyle guidance, and prescriptions for anti-obesity medications, all through a singular, user-friendly interface. The program, now featuring Wegovy® at an accessible monthly cost of $499, is expected to yield improved patient outcomes by making essential obesity treatments more attainable.

Justin Schreiber, Chairman and CEO of LifeMD, emphasized that the partnership with NovoCare® Pharmacy enhances their weight management initiative significantly, as it removes barriers to accessing critical medications for patients. With rising demand for effective obesity treatment options, LifeMD’s fully integrated digital care model prepares the company to deliver top-tier therapies on a national scale.

As the first GLP-1 therapy approved for chronic weight management and cardiovascular risk reduction in adults, Wegovy® represents a pivotal advancement in therapeutic options. Through this initiative, LifeMD strengthens its dedication to enhancing healthcare access and providing comprehensive, technology-driven obesity care, enabling more patients to improve their health outcomes with innovative solutions.

Related news for (LFMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.